Key facts
- This page summarizes James R. Musick's Form 3 filing for Vitro Biopharma, Inc..
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 14 Nov 2022, 13:28.
James R. Musick - 11 Nov 2022 Form 3 Insider Report for Vitro Biopharma, Inc.
- Reporting relationship
- Chief Science Officer, Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 11 Nov 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ James R. Musick
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
James R. Musick filed Form 3 for Vitro Biopharma, Inc. on 14 Nov 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
No ticker
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,340,498
- Date
- 11 Nov 2022
- Ownership
- Direct
No ticker
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 22,727,635
- Date
- 11 Nov 2022
- Ownership
- By Trust
- Footnotes
- F1
No ticker
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,956,849
- Date
- 11 Nov 2022
- Ownership
- By Spouse
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No ticker
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,300,000
- Exercise price
- $0.0500
- Footnotes
- F2
No ticker
holding
Derivative
Employee Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,000,000
- Exercise price
- $0.5000
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Shares are held by the James R. Musick Trust, of which James R. Musick serves as the sole trustee and beneficiary.
Footnote F2
The option became exercisable as to (i) 860,000 shares on May 1, 2018, (ii) 860,000 shares on May 1, 2019, (iii) 860,000 shares on May 1, 2020, (iv) 860,000 shares on May 1, 2021, and (v) 860,000 shares on May 1, 2022.
Footnote F3
The option became exercisable as to 200,000 shares on November 30, 2021, and will become exercisable as to (i) 200,000 shares on November 30, 2022, (ii) 200,000 shares on November 30, 2023, (iii) 200,000 shares on November 30, 2024 and (iv) 200,000 shares on November 30, 2025.